COPD Flashcards
3rd cause of death in US
COPD (4th in world)
inflammation causes
small airway dz and parenchymal destruction –>air flow limitation
small airway dz –>
airway inflammation and airway remodeling
parenchymal destruction –>
loss of alveolar attachments and decreased of elastic recoil
pursed lip breathing is a/w
emphysema
hypoxemia and respiratory acidosis and hypercarbia more common w/
chronic bronchitis
corpulmonale from pulmonary HTN
chronic bronchitis
blue bloaters
chronic bronchitis
pink puffers
emphysema
chronic bronchitis (CB)
chronic productive cough for 3 months during 2 consecutive yrs with no other cause
obstruction in CB
inspiratory and expiratory
emphysema
pathologic enlargement of the air spaces distal to the terminal bronchioles due to DESTRUCTION OF ALVEOLAR WALL
obstruction is emphysema
exhalation
inflammation by neutrophils a/w
CB
inflammation by eosinophil a/w
asthma
persistent to sever cough and sputum in
CB
dyspnea in emphysema
progressive, constant, sever
dyspnea in CB
intermittent, mild to moderate
sputum appearance in CB vs. emphysema
mucopurulant in CB vs clear-mucoid in emphysema
cardinal symp of COPD
dyspnea, chronic cough, sputum
genetic risk factor of COPD
alpha 1-antitrypsin def.
polycythemia on CBC
COPD
hallmark of dx of COPD
PFTs
CXR findings for emphysema
- hyperinflation ~w/bullae2. flattening of diaphragm 3. enlargement of retrosternal air space
CXR findings for CB
- cardiac enlargement 2. pulm congestion 3. increased lung markings
hyperinflation ~w/bullae
emphysema
cardiac enlargement
CB
flattening of diaphragm
emphysema
enlargement of retrosternal air space
emphysema
increased lung markings
CB
pulm congestion
CB
PFTs
FVC (forced vital capacity), FEV1 (forced expiratory volume in 1 sec), FEV1/FVC
FVC in COPD
normal (vs. low in restrictive dz)
FEV1 is decreased in
obstructive dz
normal value of FEV1/FVC
70-80%
decreased FEV1 with nl FVC
obstructive dz
5 A approach to smoking cessation
ask about tobacco, advise to quit, access willingness, assist , arrange f/u and support
mainstay of COPD tx
bronchodilators (B2 agonist and anticholinergics)
PDE-4 inhibitor
anti-inflammatory effect-inhibits infiltration
Roflumiast
PDE- used in refractory cases
mucolytic agents
not for out pt. used in pt w/ thick, tenacious pulmonary secretion
antiprotease therapy
for pts w. alpha1-antitrypsin def.
indications for O2 therapy
pO2 < 55 or O2 sat <88%
purse lip breathing for COPD
more air expelled
most common organism for lower RI
H flu, S pnemo, Moraxella cath, pseudomonas aeruginosa